<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In order to detect the potential implication of the endocannabinoid system in the analgesic activity of LEO, inhibition of the FAAH and MAGL enzymes was tested. LEO showed a dose-dependent response in the enzymatic bioassays (
 <xref rid="fig4" ref-type="fig" class="xref">Figure 4A</xref>). The reference substance JZL 195 provided by Cayman showed a very similar profile both in the FAAH and MAGL enzymes with an IC50 value between 0.01 and 0.1 μM (
 <xref rid="fig4" ref-type="fig" class="xref">Figure 4B</xref>). LEO was less potent than the inhibitor but was able to inhibit both enzymes, particularly FAAH (
 <xref rid="fig4" ref-type="fig" class="xref">Figure 4A</xref>). Pre-treatment with the CB1 receptor antagonist AM251 (4 mg/kg) significantly attenuated LEO-induced anti-allodynic effect (
 <xref rid="fig4" ref-type="fig" class="xref">Figure 4C</xref>).
</p>
